.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
FOURIER evaluated the PCSK9 inhibitor evolocumab in more than 27,000 patients with established atherosclerotic cardiovascular disease already receiving statin therapy. Evolocumab produced a profound reduction in LDL cholesterol and significantly reduced the risk of major cardiovascular events compared with placebo. The trial was important for demonstrating that additional LDL lowering beyond statin therapy can translate into incremental clinical benefit. For internists, the practical implication is that lipid management should be driven by overall ASCVD risk and achieved LDL-C rather than a binary decision about statin use. Patients with established disease who remain above individualized lipid targets may require combination therapy. Cost, access, adherence, injection preferences and absolute baseline risk all influence whether a PCSK9 inhibitor is appropriate. FOURIER also supports the concept that there is no obvious threshold at which further LDL reduction ceases to matter within the ranges studied. In routine practice, the first challenge remains consistent implementation of high-intensity statin therapy and verification of adherence before escalation.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
FOURIER evaluated the PCSK9 inhibitor evolocumab in more than 27,000 patients with established atherosclerotic cardiovascular disease already receiving statin therapy. Evolocumab produced a profound reduction in LDL cholesterol and significantly reduced the risk of major cardiovascular events compared with placebo. The trial was important for demonstrating that additional LDL lowering beyond statin therapy can translate into incremental clinical benefit. For internists, the practical implication is that lipid management should be driven by overall ASCVD risk and achieved LDL-C rather than a binary decision about statin use. Patients with established disease who remain above individualized lipid targets may require combination therapy. Cost, access, adherence, injection preferences and absolute baseline risk all influence whether a PCSK9 inhibitor is appropriate. FOURIER also supports the concept that there is no obvious threshold at which further LDL reduction ceases to matter within the ranges studied. In routine practice, the first challenge remains consistent implementation of high-intensity statin therapy and verification of adherence before escalation.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
